Divergent RET- and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC: A Case Report

JCO Precis Oncol. 2021 Nov:5:939-942. doi: 10.1200/PO.21.00083.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Acrylamides / therapeutic use*
  • Aniline Compounds / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / genetics
  • Drug Resistance, Neoplasm
  • ErbB Receptors / genetics
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Middle Aged
  • Mutation
  • Proto-Oncogene Proteins B-raf / physiology
  • Proto-Oncogene Proteins c-ret / physiology

Substances

  • Acrylamides
  • Aniline Compounds
  • Antineoplastic Agents
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors
  • Proto-Oncogene Proteins c-ret
  • RET protein, human
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf